GlassScriptPhysician profile
Kenneth Spicklemire
NPI 1548370570
$949.71
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $914 · 2021: $36.20.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $163.44 | 2019 | |
| Novo Nordisk INC | $143.77 | 2019 | |
| Glaxosmithkline, LLC. | $135.52 | 2019 | |
| Lilly USA, LLC | $113.23 | 2019 | |
| Pfizer INC. | $78.00 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $67.16 | 2019 | |
| Abbvie INC. | $50.06 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.20 | 2019 | |
| Eisai INC. | $25.81 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $25.14 | 2019 | |
| Sanofi-Aventis U.S. LLC | $23.79 | 2019 | |
| Sanofi Pasteur INC. | $14.84 | 2019 | |
| Therapeuticsmd, INC. | $13.92 | 2019 | |
| Janssen Pharmaceuticals, INC | $12.70 | 2019 | |
| Avanir Pharmaceuticals, INC. | $12.66 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $11.91 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $11.32 | 2019 | |
| Merck Sharp & Dohme LLC | $11.24 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Spicklemire listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.